Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
7 hedge funds and large institutions have $19.2M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.19% less ownership
Funds ownership: 13.99% → 12.8% (-1.2%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
70% less capital inflows, than outflows
Capital inflows: $683K | Capital outflows: $2.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$531K |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
+$141K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.37K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZP
Zimmer Partners
New York
|
-$1.26M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$657K |
| 3 |
Millennium Management
New York
|
-$297K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$34K |
| 5 |
1W
1776 Wealth
Atlanta,
Georgia
|
-$1K |
AYLA Hedge Fund Activity: Q3 2020 in Review
7 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q3 2020, worth a combined $19.2M — up 7.1% from $17.9M a quarter earlier.
Fund positioning in AYLA was balanced in Q3 2020: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $531K. The largest seller was Zimmer Partners, exiting entirely with an estimated $1.26M sold.
- 7 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $19.2M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q3 2020, up 7.1% quarter-over-quarter.
- 3 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 3 closed out, a net change of 0 holders.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Sio Capital Management, an estimated $531K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Zimmer Partners, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2020.